Johnson & Johnson MedTech today announced the promotion of Ahmet Tezel, Ph.D., to the position of Company Group Chairman and Global Head of MedTech Innovation and R&D.
Tezel will replace Peter Shen, Ph.D., who will retire from the role at the end of this year after a J&J career spanning more than 25 years.
Tezel will join the Medtech global leadership team and report to J&J MedTech EVP and Worldwide Chair Ashley McEvoy as the unit focuses on making its products and services “smarter, less invasive, and more personalized,” the company said in a news release.
Tezel currently serves as worldwide VP of R&D for J&J Medtech’s Ethicon business. Under his leadership, the Ethicon R&D pipeline value increased by more than 300%, the company said.
“Ahmet also played an integral role in creating synergies between Ethicon and the Robotics and Digital Solutions teams to enhance integrations of technology platforms and utilization of product development best practices,” the company said. “Ahmet joined Johnson & Johnson with broad experience in the medical technology industry including a strong history of driving innovation strategy, delivering new products to market as well as retaining and advancing key talent. He is a Credo-based leader who is dedicated to developing people and creating an inclusive work environment.”
Tezel previously held R&D leadership roles at Alcon and Allergan. He has a Ph.D. in chemical engineering from the University of California, Santa Barbara, in transdermal drug delivery and vaccination, as well as Bachelor of Science and Master of Science degrees in chemical engineering from Bogazici University in Istanbul, Turkey.
Tezel and his family will continue to live in Summit, New Jersey.
New Brunswick, New Jersey-based J&J MedTech is the second-largest medical device manufacturer in the world, according to Medical Design & Outsourcing‘s latest Medtech Big 100 ranking. The Johnson & Johnson (NYSE:JNJ) unit has about 75,000 employees and reported $27.1 billion in annual revenue for the fiscal year ended Jan. 3, 2022.